ES2253398T3 - Camptotecinas liposomales mejoradas y sus usos. - Google Patents

Camptotecinas liposomales mejoradas y sus usos.

Info

Publication number
ES2253398T3
ES2253398T3 ES01949169T ES01949169T ES2253398T3 ES 2253398 T3 ES2253398 T3 ES 2253398T3 ES 01949169 T ES01949169 T ES 01949169T ES 01949169 T ES01949169 T ES 01949169T ES 2253398 T3 ES2253398 T3 ES 2253398T3
Authority
ES
Spain
Prior art keywords
topotecan
dose
liposomal
drug
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01949169T
Other languages
English (en)
Spanish (es)
Inventor
Thomas D. Madden
Sean C. Semple
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inex Pharmaceuticals Corp
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Application granted granted Critical
Publication of ES2253398T3 publication Critical patent/ES2253398T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES01949169T 2000-06-30 2001-06-29 Camptotecinas liposomales mejoradas y sus usos. Expired - Lifetime ES2253398T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21555600P 2000-06-30 2000-06-30
US215556P 2000-06-30
US26461601P 2001-01-26 2001-01-26
US264616P 2001-01-26

Publications (1)

Publication Number Publication Date
ES2253398T3 true ES2253398T3 (es) 2006-06-01

Family

ID=26910152

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01949169T Expired - Lifetime ES2253398T3 (es) 2000-06-30 2001-06-29 Camptotecinas liposomales mejoradas y sus usos.

Country Status (12)

Country Link
US (7) US7060828B2 (enExample)
EP (2) EP1299085B1 (enExample)
JP (3) JP2004501955A (enExample)
CN (1) CN1245977C (enExample)
AT (2) ATE309787T1 (enExample)
AU (3) AU7038501A (enExample)
CA (2) CA2412795C (enExample)
DE (2) DE60115044T2 (enExample)
ES (1) ES2253398T3 (enExample)
IL (2) IL153676A0 (enExample)
MX (1) MXPA02012817A (enExample)
WO (2) WO2002002078A2 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7452550B2 (en) * 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
EP1299085B1 (en) * 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Improved liposomal camptothecins and uses thereof
HUP0302352A3 (en) 2000-11-09 2007-03-28 Neopharm Sn-38 lipid complexes and methods of use
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
JP2005502653A (ja) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
WO2004054499A2 (en) * 2002-08-02 2004-07-01 Transave, Inc. Platinum aggregates and process for producing the same
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
EP1643972A4 (en) * 2003-06-27 2010-01-20 Smithkline Beecham Corp STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD
ES2329374T3 (es) 2003-11-14 2009-11-25 Het Nederlands Kanker Instituut (The Netherlands Cancer Institute) Formulaciones farmaceuticas que utilizan esfingolipidos de cadena corta y usos de las mismas.
WO2005072776A2 (en) * 2004-01-30 2005-08-11 Instytut Farmaceutyczny Liposomal formulations of the antineoplastic agents
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
AU2005223654A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
AU2005251691A1 (en) * 2004-05-17 2005-12-22 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
AU2005245018A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
NZ551748A (en) * 2004-06-01 2010-02-26 Yakult Honsha Kk Irinotecan formulation
US20070082042A1 (en) * 2004-08-06 2007-04-12 Deok-Hoon Park Multiple-layered liposome and preparation method thereof
CN101072588B (zh) * 2004-10-06 2012-11-28 不列颠哥伦比亚抗癌机构 用于治疗癌症的具有改善的药物保留的脂质体
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
KR20070089693A (ko) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 지질-기재 플래티넘 화합물 제형을 복막내 투여하여 암을치료하는 방법
CN100348194C (zh) * 2005-07-26 2007-11-14 康辰医药发展有限公司 盐酸洛拉曲克的脂质体制剂及其制备方法
CN100375621C (zh) * 2005-11-04 2008-03-19 唐星 长春瑞滨脂质微球注射液及其制备方法
US9107824B2 (en) * 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
US8067432B2 (en) 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
US20100093873A1 (en) * 2008-10-02 2010-04-15 Goldfischer Sidney L Methods of improving therapy of perfluorocarbons (PFC)
JPWO2010058840A1 (ja) * 2008-11-20 2012-04-19 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
US9542001B2 (en) 2010-01-14 2017-01-10 Brainlab Ag Controlling a surgical navigation system
CN103442565B (zh) * 2010-10-29 2016-08-10 健康研究股份有限公司 使用用于癌症治疗的化合物fl118制剂的非水溶性化合物新型制剂及方法
PL226015B1 (pl) 2011-03-03 2017-06-30 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna
US12004868B2 (en) * 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10449193B2 (en) * 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US8753674B2 (en) * 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10349884B2 (en) * 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
EP2892524B1 (en) 2012-09-04 2020-11-25 Eleison Pharmaceuticals, LLC Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
WO2014081887A1 (en) 2012-11-20 2014-05-30 Spectrum Pharmaceuticals Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
MA38687A1 (fr) * 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
JP6895252B2 (ja) 2013-12-18 2021-06-30 サインパス ファルマ, インク.Signpath Pharma, Inc. 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
EP3151837B1 (en) 2014-06-03 2023-03-15 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
PT3229776T (pt) * 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CA2940470C (en) * 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
EP3448374B1 (en) 2016-04-27 2025-02-12 Signpath Pharma Inc. Prevention of drug-induced atrio-ventricular block
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
WO2018045317A1 (en) 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
WO2018181963A1 (ja) 2017-03-31 2018-10-04 富士フイルム株式会社 リポソーム組成物および医薬組成物
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
US12246018B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
EP3749317A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC PEMETREXED ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
CA3090943A1 (en) * 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US12290518B2 (en) 2018-02-14 2025-05-06 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
TWI737974B (zh) * 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
PL3811931T3 (pl) 2018-06-20 2024-11-18 Fujifilm Corporation Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej
WO2020071349A1 (ja) 2018-10-01 2020-04-09 富士フイルム株式会社 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬
WO2020205473A1 (en) 2019-03-29 2020-10-08 Decerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
WO2020226960A1 (en) 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
JP2023508881A (ja) * 2019-12-20 2023-03-06 トランスレイト バイオ， インコーポレイテッド Ｍｒｎａ担持脂質ナノ粒子を調製する改善されたプロセス
TW202140043A (zh) 2020-01-15 2021-11-01 美商戴瑟納製藥股份有限公司 4’-o-亞甲基膦酸酯核酸及其類似物
JP2023537499A (ja) 2020-08-04 2023-09-01 ディセルナ ファーマシューティカルズ インコーポレイテッド オリゴヌクレオチドの全身送達
EP4349337A4 (en) 2021-05-24 2024-08-28 FUJIFILM Corporation Anti-tumor agent
WO2022250015A1 (ja) 2021-05-24 2022-12-01 富士フイルム株式会社 処置剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023087A (en) * 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
AU7128887A (en) * 1986-02-10 1987-08-25 Liposome Technology, Inc. Controlled-release liposome delivery system
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
EP0721328A4 (en) 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
US6855331B2 (en) * 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
EP0784474A2 (en) * 1994-10-05 1997-07-23 Glaxo Wellcome Inc. Parenteral pharmaceutical compositions containing gf120918a
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
JP4335310B2 (ja) * 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998017256A1 (en) 1996-10-22 1998-04-30 Dmitri Kirpotin Compound-loaded liposomes and methods for their preparation
US5837282A (en) * 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
WO1999013816A2 (en) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Liposomal camptothecin formulations
CA2346879A1 (en) 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6352996B1 (en) * 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
EP1299085B1 (en) * 2000-06-30 2005-11-16 Inex Pharmaceuticals Corp. Improved liposomal camptothecins and uses thereof
CZ20031262A3 (en) * 2000-10-16 2004-03-17 Neopharm, Inc. Liposomal formulation of mitoxantrone
US6825206B1 (en) * 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline

Also Published As

Publication number Publication date
EP1299085A2 (en) 2003-04-09
EP1299085B1 (en) 2005-11-16
CA2412790C (en) 2012-11-06
CN1446079A (zh) 2003-10-01
CA2412790A1 (en) 2002-01-10
CA2412795C (en) 2012-10-02
WO2002002078A2 (en) 2002-01-10
US7060828B2 (en) 2006-06-13
US20130136787A1 (en) 2013-05-30
MXPA02012817A (es) 2004-07-30
ATE309786T1 (de) 2005-12-15
EP1299084A2 (en) 2003-04-09
US7244448B2 (en) 2007-07-17
DE60115045D1 (de) 2005-12-22
AU2001270385B2 (en) 2006-05-25
JP2012092148A (ja) 2012-05-17
JP2014088444A (ja) 2014-05-15
AU7038501A (en) 2002-01-14
US20110086826A1 (en) 2011-04-14
US20060269594A1 (en) 2006-11-30
JP2004501955A (ja) 2004-01-22
US20020119990A1 (en) 2002-08-29
DE60115044T2 (de) 2006-08-03
US20020110586A1 (en) 2002-08-15
IL153676A0 (en) 2003-07-06
IL153676A (en) 2007-06-17
WO2002002077A3 (en) 2002-12-12
CN1245977C (zh) 2006-03-22
EP1299084B1 (en) 2005-11-16
US20060093662A1 (en) 2006-05-04
DE60115044D1 (de) 2005-12-22
US20040170678A1 (en) 2004-09-02
ATE309787T1 (de) 2005-12-15
CA2412795A1 (en) 2002-01-10
WO2002002077A2 (en) 2002-01-10
DE60115045T2 (de) 2006-08-03
AU2001270413A1 (en) 2002-01-14
WO2002002078A3 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
US7060828B2 (en) Liposomal camptothecins and uses thereof
ES2704986T3 (es) Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
ES2198970T3 (es) Inhibidores de topoisomerasa atrapados en liposomas.
ES2550759T3 (es) Formulaciones farmacológicas de platino mejoradas
AU2001270385A1 (en) Liposomal antineoplastic drugs and uses thereof
ES2574231T3 (es) Uso de liposomas catiónicos que comprenden paclitaxel
KR100851957B1 (ko) 벤조퀴나졸린 티미딜레이트 신타제 억제제의 리포솜 제형
ES2500590T3 (es) Agente para aumentar el efecto antitumoral que comprende una preparación de liposoma de oxaliplatino y agente antitumoral que comprende la preparación de liposoma
WO2025019344A2 (en) Combinations comprising an atr inhibitor and a parp inhibitor and methods of use thereof
ES2777223T3 (es) Composición de liposoma para liberación controlada de fármaco
Fatima et al. Ionic gradient liposomes: Recent advances in the stable entrapment and prolonged released of local anesthetics and anticancer drugs
JP2006513984A (ja) 医薬的に活性な、脂質をベースにしたｓｎ３８製剤
ES2394264T3 (es) Meta-arsenito de sodio para uso en el tratamiento de enfermedades neoplásicas metastásicas
HK1252369A1 (zh) 利用纳米颗粒治疗肿瘤的组合物和方法
ES2303114T3 (es) Metodo para cargar medicamentos en liposomas.
WO2008038291A1 (en) Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
US7452550B2 (en) Liposomal antineoplastic drugs and uses thereof
Sengupta et al. Encapsulation in cationic liposomes enhances antitumour efficacy and reduces the toxicity of etoposide, a topo-isomerase II inhibitor
Harrington et al. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours
US20040219201A1 (en) Tempamine compositions and methods of use